zodasiran Injection
DrugARO-ANG3 Injection
Other names: ARO-ANG3
NCT Number: NCT07037771
This multicenter, randomized, placebo-controlled study will evaluate the efficacy and safety of zodasiran subcutaneous (SC) injection in subjects 12 years of age and older with genetically or clinically diagnosed Homozygous familial hypercholesterolemia (HoFH). After completion of the double blind (DB) treatment period subjects will be eligible to continue in the optional open-label extension (OLE) period of the study. All placebo subjects who opt to continue will transition to active drug during the OLE Period.
Interested in participating?
Request Info12 year and older
All sexes
Interventional
Phase 3
Research Site 13, Camperdown, New South Wales, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
NOTE: Additional Inclusion/exclusion criteria may apply per protocol
ARO-ANG3 Injection
Other names: ARO-ANG3
sterile normal saline (0.9% NaCl)
Time frame: Baseline, Month 12
Time frame: Baseline, Month 12
Time frame: Baseline, Month 12
Time frame: Baseline, Month 12
Time frame: Baseline, Month 12
Time frame: Baseline, Month 12
Time frame: Baseline, Month 12
Time frame: Baseline, Month 12
Time frame: Baseline, Month 12
Time frame: Month 12
Time frame: Month 12
Time frame: Month 12
Time frame: Baseline, Day 1, Months 1, 2, 3, 4.5, 6, 7.5, 9, 10.5, and 12
Time frame: Baseline, Day 1, Months 1, 2, 3, 4.5, 6, 7.5, 9, 10.5, and 12
Time frame: Baseline, Month 12
Contact information is provided by the study sponsor or research team.
Arrowhead Pharmaceuticals
Industry
Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01109368
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
New York, United States
View Trial DetailsNCT04815005
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06125847
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
Xi'an, Shaanxi, China
View Trial DetailsNCT07473843
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias
View Trial Details